Literature DB >> 30563370

Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported.

Joel D Handley1,2, Hedley Ca Emsley2,3.   

Abstract

BACKGROUND: Intracranial venous thrombosis (ICVT) accounts for around 0.5% of all stroke cases. There have been no previously published studies of the International Classification of Diseases, Tenth Edition (ICD-10) validation for the identification of ICVT admissions in adults.
OBJECTIVE: The aims of this study were to validate and quantify the performance of the ICD-10 coding system for identifying cases of ICVT in adults and to derive an estimate of incidence.
METHOD: Administrative data were collected for all patients admitted to a regional neurosciences centre over a 5-year period. We searched for the following ICD-10 codes at any position: G08.X (intracranial and intraspinal phlebitis and thrombophlebitis), I67.6 (non-pyogenic thrombosis of intracranial venous system), I63.6 (cerebral infarction due to cerebral venous thrombosis, non-pyogenic), O22.5 (cerebral venous thrombosis in pregnancy) and O87.3 (cerebral venous thrombosis in the puerperium).
RESULTS: Sixty-five admissions were identified by at least one of the relevant ICD-10 codes. The overall positive predictive value (PPV) for confirmed ICVT from all of the admissions combined was 92.3% (60 out of 65) with the results for each code as follows: G08.X 91.5% (54 of 59), O22.5 100% (4 of 4), I67.6 100% (1 of 1), I63.6 100% (1 of 1) and O87.3 100% (1 of 1). There were 40 unique cases of ICVT over a 5-year period giving an annual incidence of ICVT of 5 per million.
CONCLUSIONS: All codes gave a high PPV. IMPLICATIONS FOR PRACTICE: As demonstrated in previous studies, the incidence of ICVT may be higher than previously thought.

Entities:  

Keywords:  ICD-10; cerebral thrombosis; clinical coding; incidence; sinus thrombosis; venous thrombosis

Mesh:

Year:  2018        PMID: 30563370     DOI: 10.1177/1833358318819105

Source DB:  PubMed          Journal:  Health Inf Manag        ISSN: 1833-3583            Impact factor:   3.185


  9 in total

1.  Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States.

Authors:  Fadar Oliver Otite; Smit Patel; Richa Sharma; Pushti Khandwala; Devashish Desai; Julius Gene Latorre; Emmanuel Oladele Akano; Nnabuchi Anikpezie; Saef Izzy; Amer M Malik; Dileep Yavagal; Priyank Khandelwal; Seemant Chaturvedi
Journal:  Neurology       Date:  2020-08-26       Impact factor: 9.910

2.  Epidemiology, Clinical Features, and Outcome in a Cohort of Adolescents With Cerebral Venous Thrombosis.

Authors:  Julia Devianne; Nicolas Legris; Isabelle Crassard; Celine Bellesme; Yannick Bejot; Celine Guidoux; Fernando Pico; David Germanaud; Michael Obadia; Diana Rodriguez; Philippe Tuppin; Manoelle Kossorotoff; Christian Denier
Journal:  Neurology       Date:  2021-09-20       Impact factor: 9.910

3.  Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score.

Authors:  Piers Klein; Liqi Shu; Thanh N Nguyen; James E Siegler; Setareh Salehi Omran; Alexis N Simpkins; Mirjam Heldner; Adam de Havenon; Hugo J Aparicio; Mohamad Abdalkader; Marios Psychogios; Maria Cristina Vedovati; Maurizio Paciaroni; Rascha von Martial; David S Liebeskind; Diana Aguiar de Sousa; Jonathan M Coutinho; Shadi Yaghi
Journal:  J Stroke       Date:  2022-09-30       Impact factor: 8.632

4.  Positive Predictive Value of ICD-10 Codes for Cerebral Venous Sinus Thrombosis in Taiwan's National Health Insurance Claims Database.

Authors:  Shu-Chen Liao; Shih-Chieh Shao; Edward Chia-Cheng Lai; Swu-Jane Lin; Wei-I Huang; Cheng-Yang Hsieh
Journal:  Clin Epidemiol       Date:  2022-01-03       Impact factor: 4.790

5.  Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study.

Authors:  Sharifa Nasreen; Andrew J Calzavara; Maria E Sundaram; Shannon E MacDonald; Christiaan H Righolt; Menaka Pai; Thalia S Field; Lily W Zhou; Sarah E Wilson; Jeffrey C Kwong
Journal:  BMJ Open       Date:  2021-12-17       Impact factor: 2.692

6.  Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients.

Authors:  Susan C Weller; Laura Porterfield; John Davis; Gregg S Wilkinson; Lu Chen; Jacques Baillargeon
Journal:  BMJ Open       Date:  2022-02-09       Impact factor: 2.692

7.  Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019.

Authors:  Amanda B Payne; Alys Adamski; Karon Abe; Nimia L Reyes; Lisa C Richardson; William Craig Hooper; Laura A Schieve
Journal:  Res Pract Thromb Haemost       Date:  2022-03-07

8.  A near real-time electronic health record-based COVID-19 surveillance system: An experience from a developing country.

Authors:  Abbas Sheikhtaheri; Seyed Mohammad Tabatabaee Jabali; Ehsan Bitaraf; Alireza TehraniYazdi; Ali Kabir
Journal:  Health Inf Manag       Date:  2022-07-15       Impact factor: 3.778

9.  Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases.

Authors:  Maxime Taquet; Masud Husain; John R Geddes; Sierra Luciano; Paul J Harrison
Journal:  EClinicalMedicine       Date:  2021-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.